GET DAILY SIGNALSWhy Is Artivion (AORT) Stock Down -20.25% Today?
Key Takeaways
- AORT shares fell roughly 20.25% in Thursday's session, sliding from a prior close of $25.33 to about $20.20.
- The decline followed third-quarter results that beat on revenue but exposed a sharp margin squeeze, a GAAP net loss, and negative free cash flow.
- Management flagged a 2027 headwind as the PerClot supply agreement with Baxter winds down, trimming an estimated $10 million in annual revenue.
- Analysts cut price targets, with Citizens JMP lowering its target to $42 from $48 and Canaccord cutting to $30 from $40, while both maintained positive ratings.
- Trading volume ran well above average as investors reassessed the company's near-term growth and profitability trajectory.
- For more context, explore Price Targets, Earnings, and Forecast pages on Tickeron.
- You can also track how AI trading systems are positioned by reviewing the Trending AI Robots section.
Opening Summary
AORT, the ticker for Artivion, Inc., a medical device company focused on cardiac and vascular surgery products for aortic disease, dropped sharply on Thursday. Shares closed the prior session at $25.33 and traded near $20.20, a decline of approximately 20.25%. The move confirmed a pronounced downward shift in market sentiment, driven primarily by a third-quarter earnings report that revealed contracting margins, a swing to a GAAP net loss, and a newly disclosed 2027 revenue headwind even as the top line exceeded expectations.
Earnings Results Exposed a Margin Squeeze
The catalyst for the sell-off was Artivion's third-quarter report. Revenue rose 9% year over year on a constant-currency basis to $123.8 million, edging past consensus estimates near $121 million. Adjusted earnings per share came in at $0.08, but the headline beat masked weaker underlying profitability. Gross margin fell to 61.4% from 65.6% a year earlier, pressured by unfavorable product mix and early ramp costs at the company's On-X and NEXUS manufacturing facilities. Adjusted EBITDA declined 8% to $22.5 million, and on a GAAP basis the company swung to a net loss of $7.9 million from net income of $6.5 million a year ago.
Free Cash Flow and Leverage Concerns
Investors also reacted to a sharp deterioration in cash generation. Free cash flow was negative $17.6 million in the quarter, compared with positive $17.7 million in the prior-year period, reflecting a portion of the AMDS PMA milestone payment and Endospan integration costs. Net leverage stood at 3.5x at quarter-end, amplifying concerns about the company's balance-sheet flexibility as it invests ahead of product launches.
New 2027 PerClot Headwind
Adding to the pressure, management disclosed that the transitional supply agreement with Baxter for its PerClot product will expire in February 2027, eliminating roughly $10 million in annual revenue. Executives told investors to reduce prior revenue growth expectations by about 2 percentage points and EBITDA growth expectations by about 4 percentage points for 2027. While full-year 2026 guidance was narrowed to $484 million–$492 million in revenue and $93 million–$98 million in adjusted EBITDA with unchanged midpoints, the forward-looking adjustment weighed on the stock.
Analyst Reactions and Price-Target Cuts
Sell-side firms responded by trimming targets. Citizens JMP lowered its price target to $42 from $48 while keeping an Outperform rating, and Canaccord cut its target to $30 from $40 while maintaining a Buy. The reductions reflected softer core stent-graft growth trends and the anticipated PerClot exit rather than a fundamental loss of confidence in the company's longer-term pipeline, but the combined effect reinforced the negative market reaction.
Market Context and Trading Activity
Trading volume was elevated well above the stock's typical daily average of roughly 600,000–650,000 shares, signaling heavy institutional repositioning. The move diverged from the broader market and reflected company-specific concerns rather than sector-wide weakness, as investors focused on the margin compression and cash-flow reversal. The decline pushed shares near the lower end of their recent range, close to the 52-week low of $19.16 and well below the roughly $26.45 close reached two sessions earlier.
What Comes Next for AORT
Looking ahead, attention turns to the ARTIZEN trial, with first 30-patient data expected as a late-breaker at the AATS Aortic Symposium on November 19. The U.S. commercial launch of the NEXUS aortic arch stent graft system, slated for January 2027, remains a key catalyst, with surgeon training expected to begin in December. However, investors will be watching whether margins stabilize, whether AMDS starter-set adoption overcomes administrative hurdles, and how effectively the company manages leverage into 2027. The PerClot wind-down and a currency headwind in the fourth quarter add near-term uncertainty to the growth outlook.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots drawn from hundreds of systems covering thousands of tickers. Only the strongest performers under current market conditions are featured, with bots differing by strategy, timeframe, performance metrics, and traded symbols. Traders seeking data-driven signals may find it useful to explore how these automated systems are positioned across the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AORT in +12.17% Uptrend, advancing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AORT advanced for three days, in 221 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for AORT just turned positive on October 14, 2026. Looking at past instances where AORT's MACD turned positive, the stock continued to rise in 34 of 47 cases over the following month. The odds of a continued upward trend are 72%.
AORT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for AORT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 22 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 62 cases where AORT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 77%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AORT as a result. In 54 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.
AORT moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AORT crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AORT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
The Aroon Indicator for AORT entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.211) is normal, around the industry mean (4.137). AORT's P/E Ratio (-404.200) is considerably lower than the industry average of (2.620). Projected Growth (PEG Ratio) (4.200) is also within normal values, averaging (11.253). Dividend Yield (0.006) settles around the average of (0.011) among similar stocks. P/S Ratio (2.603) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. AORT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AORT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of cryopreserved human tissue for vascular transplant applications
Industry MedicalNursingServices